Atrial fibrillation (AF) is associated with a high incidence of strokes/thromboembolism. The CHADS 2 score assigns points for several clinical variables to identify stroke risk. The CHA 2 DS 2 -VAS C score uses the same variables but also incorporates age 65 to 74, female gender, and vascular disease in an effort to provide a more refined risk of stroke/thromboembolism. We aimed to examine oral anticoagulation (OAC) recommendations for a cohort of patients undergoing AF ablation depending upon whether thrombo-embolic risk was determined by the CHADS 2 or CHA 2 DS 2 -VAS C score.
Atrial fibrillation (AF) is frequently associated with morbidity and mortality from cerebrovascular accident (CVA)/transient ischaemic attack (TIA). 1 Randomized studies have evaluated the effects of anticoagulation with aspirin, 2 -9 antiplatelet agents, 10 and oral anticoagulation (OAC) drugs such as warfarin 3 -9 or newer agents 11 -13 on the rate of thromboembolism. Risk stratification schemes 14 -18 attempt to predict thrombo-embolic risk to identify patients who might benefit from OAC. These schemes generally divide patients into three subgroups: (i) Patients requiring no OAC (NO-OAC); (ii) Patients for whom OAC should be considered (CONSIDER-OAC); (iii) Patients who need definite OAC (DEFINITE-OAC). The most widely utilized scheme has been the CHADS 2 score, 15, 16 which incorporates one point each for congestive heart failure (CHF)/left ventricular (LV) dysfunction, hypertension, age ≥75, and diabetes and two points for prior CVA/TIA. Under the CHADS 2 schema, the recommendation is aspirin for a score of 0, aspirin or OAC for a score of 1, and OAC for a score of ≥2. The CHADS 2 scoring system has been criticized 17 because it does not provide enough granularity for patients in the lower risk group with CHADS 2 ¼ 1, leaving too many patients in the ambiguous group of aspirin vs. OAC and may not predict a very low-risk group who need no treatment or aspirin. CHADS 2 does not incorporate female gender, vascular disease, and age 65-74. 18 These perceived shortcomings resulted in the CHA 2 DS 2 -VAS C score, first endorsed by the 2010 European AF guidelines. 19 The 2012 European update 20 excludes females of age ,65 if that is the only risk factor. The recent Canadian guidelines 21 comment on the lack of value of female gender in the score and states that patients achieving a CHA 2 DS 2 -VAS C score of 1 because of gender or vascular disease are low risk and should receive aspirin. Although there have been population-based statistical justifications of the improved ability of the CHA 2 DS 2 -VAS C score to predict stroke, 22 -26 neither the CHA 2 DS 2 -VAS C nor the CHADS 2 have been evaluated in a prospective randomized trial to select anticoagulant strategies. While the benefits of OAC are obvious, increasing use of OAC is associated with an increased incidence of intracerebral haemorrhage 27 and, for warfarin, anticoagulation intensity correlates with the risk of death from intracerebral haemorrhage. 28 Furthermore, including vascular disease in a stroke-risk prediction model might improve prediction of all-cause ischaemic strokes but not necessarily thrombo-embolic strokes. Recommending OAC on the basis of vascular disease might not reduce strokes due to vascular disease. In the present study, we apply the CHA 2 DS 2 -VAS C score to a cohort of patients undergoing AF ablation to determine the changes in recommended anticoagulation strategy compared with the CHADS 2 score.
Methods

Patient population
The subjects were consecutive patients undergoing AF ablation at Sequoia Hospital, Redwood City, California, USA, from 10 October 2003 to 31 December 2011. All the patients signed written informed consent for their ablation procedure. Data collection was prospective and approved by the hospital IRB. Atrial fibrillation type was categorized as paroxysmal (lasting ,1 week), persistent (AF lasting .1 week and ,1 year or requiring pharmacological/electrical cardioversion in ,1 week), and long-standing persistent (AF lasting .1 year).
Data collection and analysis
For each patient we recorded age, gender, AF duration and type, prior CVA/TIAs, left atrial (LA) size, and comorbidities including hypertension, diabetes, prior myocardial infarction (MI), peripheral vascular disease, and CHF/LV dysfunction. We calculated the CHADS 2 score for each patient: 1 point each CHF/LV dysfunction, hypertension, age ≥75, and diabetes and 2 points for prior stroke/TIA. We also calculated the CHA 2-DS 2 -VAS C score for each patient: 1 point each for CHF/LV dysfunction, hypertension, age 65 -74, diabetes, female gender, and vascular disease (defined as prior MI, vascular disease, or aortic atherosclerosis) and 2 points for age ≥75, and for prior stroke/TIA.
Recommendations for OAC were defined as NO-OAC for a CHADS 2 or CHA 2 DS 2 -VAS C score of 0, CONSIDER-OAC for CHADS 2 or CHA 2 DS 2 -VAS C scores of 1, and DEFINITE-OAC for CHADS 2 or CHA 2 DS 2 -VAS C scores ≥2. We also examined the special categories of a CHA 2 DS 2 -VAS C score of 1 due solely to female gender (age ,65) and due to female gender of any age or vascular disease. For data analysis those patients with CHADS 2 or CHA 2-DS 2 -VAS C scores ≥2 were combined into a single group.
We examined the number of patients the CHADS 2 score placed into each of the three anticoagulation strategies. We examined each CHADS 2 score to determine how many patients the CHA 2 DS 2 -VAS C score reclassified into a different (i.e. more aggressive) anticoagulation strategy. For CHADS 2 score 0, we determined the number of patients remaining on CHA 2 DS 2 -VAS C score 0 and the number advancing to CHA 2 DS 2 -VAS C score 1 or CHA 2 DS 2 -VAS C score ≥2. For CHADS 2 score 1, we determined the number of patients remaining on CHA 2 DS 2 -VAS C score 1 and the number advancing to CHA 2 DS 2 -VAS C score ≥2.
Statistical analysis
Statistical analysis was performed using XLSTAT 2011 (Paris, France). Continuous data were described as mean + standard deviation and categorical data as counts and percentages. Cochran-Armitage trend analysis evaluated the incidence of vascular disease across CHADS 2 scores. Using analysis of variance or Cochran-Armitage trend test, we evaluated the trends for LA size, duration of AF in years, and incidence of paroxysmal, persistent, or long-standing persistent AF by CHADS 2 and CHA 2-DS 2 -VAS C scores. We did not evaluate the trend for hypertension, diabetes, CHF/LV dysfunction, and prior stroke/TIA as these comprise a fundamental part of the CHADS 2 and CHA 2 DS 2 -VAS C scoring system. We evaluated the trend for female gender and incidence of vascular disease across the CHADS 2 groups as these were not involved in the CHADS 2 scoring system. All the tests were two-sided and P , 0.05 was considered statistically significant. females with increasing scores (P , 0.0001) and also more vascular disease with increasing scores (P , 0.0001) as shown in Figure 1 .
Results
Patient population
Total cohort using CHA 2 DS 2 -VAS C compared with CHADS 2 score Changes in oral anticoagulation strategies for patients with a CHADS 2 score 5 0
The CHADS 2 scoring system assigned 569 patients (40.3%) a score of 0 indicating a recommendation of NO-OAC. For the CHA 2 DS 2 -VAS C scoring system this fell to 308 (21.8%) patients with a score of 0 and a recommendation of NO-OAC. For the 569 CHADS 2 score 0 patients, 199 (35.0%) were changed to a score of 1 using CHA 2 DS 2 -VAS C . Of these 199 patients, 74 (37.2%) were reclassified on the basis of female gender, 118 (59.3%) males were changed on the basis of age .65; while only 7 (3.5%) were changed on the basis of vascular disease (7 males, 6 with prior MI and 1 with carotid disease). Of the 569 CHADS 2 score 0 patients, 62 changed to a CHA 2 DS 2 -VAS C score of 2 indicating a recommendation of DEFINITE-OAC. Of these 62 patients, 58 (93.5%) were upgraded to a higher score and recommendation of more aggressive anticoagulation based on the combination of female gender and age .65. Only four (6.5%) males changed to a score of 2 based on vascular disease (three with prior MIs, one with carotid disease).
Of the 569 patients with a CHADS 2 score of 0, only 11 (1.93%) changed to CHA 2 DS 2 -VAS C score 1 or 2 based on vascular disease. The reason why so few patients with a CHADS 2 score of 0 changed to higher categories based upon vascular disease is demonstrated in Figure 1 . Only 1.9% of patients with a CHADS 2 score of 0 and 3.3% of those with a CHADS 2 score of 1 had vascular disease. In contrast, 9.5% of those with a CHADS 2 score ≥2 had vascular disease. This trend of increasing vascular disease with increasing 
Discussion
Our study makes two important observations. First, when compared with the CHADS 2 scoring system, the CHA 2 DS 2 -VAS C scoring system results in fewer patients in the low and intermediate thromboembolic risk groups and increases the number of patients in the DEFINITE-OAC group. Secondly, in our patient population, incorporating vascular disease into the CHA 2 DS 2 -VAS C score contributes little to the reclassification of patients' stroke risk. The incorporation of 1 point for female gender, 1 point for age 65-75, and 2 points for age ≥75 accounts for nearly all changes in the aggressiveness of anticoagulant strategy. It is not surprising that vascular disease had little effect on changing OAC recommendations, since most of the factors (diabetes, hypertension, or age ≥75) found in the CHADS 2 scoring system are associated with atherosclerotic vascular disease. Therefore, most vascular disease patients are already in the CHADS 2 score ≥2 group for whom OAC is already recommended.
Vascular disease in atrial fibrillation patients
The true incidence of vascular disease is probably grossly underestimated in AF populations when only clinically apparent disease is included in the score. This could diminish the predictive value of vascular disease as there may be many patients with silent vascular disease as severe as those with clinically diagnosed disease. Vascular disease was an independent predictor of subsequent stoke risk in a large Danish National Registry of hospitalized patients with nonvalvular AF who were not on OAC. 22 However, another study evaluating the CHA 2 DS 2 -VAS C score in AF patients taking part in several clinical trials found that vascular disease did not predict subsequent strokes. 29 The incidence of vascular disease in our study is lower than that reported in several other studies examining the CHA 2 DS 2 -VAS C score 29, 30 in hospital cohorts, which may reflect the fact that we examined a group of outpatients who were healthy enough to be considered for catheter ablation of AF. It is unknown if subsequent strokes in patients with generalized vascular disease are due to thrombo-embolic events preventable by OAC, or due to atherosclerotic/ischaemic events, not preventable by OAC.
Goals of the CHA 2 DS 2 -VAS C score
The CHA 2 DS 2 -VAS C system includes stroke-risk factors not included in the CHADS 2 score in the attempt to provide a less ambiguous decision tree for physicians deciding which AF patients require OAC. document the ability of the CHA 2 DS 2 -VAS C score to predict CVA/TIA. 22 -26 What remains uncertain is whether the large number of patients who move to higher risk classifications also benefit from OAC. A study from a large Danish National Registry showed a benefit of warfarin over aspirin in patients with a CHADS 2 score ≥0 and a CHA 2 DS 2 -VAS C score ≥1. 24 However, this study has the shortcomings of being registry-driven data obtained from patients discharged from the hospital. These findings are not equivalent to a randomized trial and may not be representative of outpatients with AF.
Evidence from randomized trials that oral anticoagulation benefits lower risk atrial fibrillation patients
There have been relatively few randomized trials directly comparing OAC and aspirin, especially in lower risk patients. Randomized trials of high-risk patients generally show that OAC is superior to aspirin. However, what is the evidence from randomized trials that lower risk patients, such as those upgraded to CONSIDER-or DEFINITE-OAC by CHA 2 DS 2 -VAS C benefit from OAC? The randomized studies of OAC in high-risk patients include the EAFT trial, 3 which randomized 669 patients with non-rheumatic AF and a recent TIA or minor ischaemic stroke and found warfarin superior to both aspirin and placebo. The AFASAK study 6 randomized 1007 patients with chronic non-valvular AF to warfarin, aspirin, or placebo. Although this study demonstrated a benefit of warfarin over both aspirin and placebo, it did not risk-stratify patients into highand low-risk groups. The BAFTA study 4 randomized 973 AF patients age .75 to warfarin or aspirin and demonstrated that for the entire cohort warfarin was superior for preventing thrombo-embolic events. Several other randomized studies have been unable to show a benefit of OAC for warfarin compared with aspirin. Although the SPAF trial showed the superiority of both aspirin and warfarin compared with placebo for preventing strokes in non-valvular AF, 4 it was unable to show a superiority of warfarin over aspirin, especially in those patients ,75 years of age. In the SPAF trial, 9 when aspirin was compared with warfarin, there were 4.6% patients having a stroke with residual on warfarin and only 4.3% having a stroke with residual on aspirin, probably due to 1.8% of patients on warfarin having an intracranial bleed vs. 0.8% on aspirin. The PTAF trial 5 randomized 729 ambulatory outpatients with non-valvular AF, an average age of 75, and no prior evidence for a thrombo-embolic event to aspirin or warfarin and showed no advantage of warfarin over aspirin. A meta-analysis 31 of 4052 patients with non-valvular AF randomized to receive OAC or aspirin showed a benefit for warfarin only for the high stroke-risk subset. High-risk patients were classified as those with hypertension, diabetes, or prior CVA/TIA. Patients without these risk factors did not benefit from taking warfarin. The AVERROES trial 13 randomized patients unsuitable for warfarin to apixiban or aspirin. Apixaban was superior for the group as a whole but there was no statistically significant advantage over aspirin in the 65 -75 year age group or in those with a CHADS 2 score of 0 or 1. Thus, it is not absolutely certain that low-to intermediate-risk patients will benefit from OAC and we should be cautious about recommending OAC for a large number of lower risk patients by using CHA 2 DS 2 -VAS C scores without data from randomized trials to document its benefit. Table 3 summarizes these randomized trials of OAC vs. aspirin. Of the trials that did not stratify for stroke risk, 5, 6, 9 only one of three showed OAC to be superior to aspirin.
Of the trials that did stratify for stroke risk, 4, 13, 31 two of three showed a benefit of OAC only in high-risk patients, and the trial enrolling only high-risk patients 3 showed a benefit of OAC. It remains to be proven by a randomized clinical trial if the newer OAC drugs are enough safer than warfarin to provide a better outcome than placebo or aspirin in lower risk patients. Even if newer OAC drugs are safer, it does not mean patients will receive them rather than warfarin when OAC is recommended by CHA 2 DS 2 -VAS C . In our clinical experience, penetration of the newer drugs is significantly reduced by Randomized trials are needed in lower risk atrial fibrillation patients
Eckman et al. 34 suggests that the stroke rate in AF patients has declined recently for all CHADS 2 scores, possibly due to the use of antihypertensive drugs and cholesterol-lowering agents. They suggest recent lower estimates of stroke risk shift the 'tipping point' such that anticoagulation with warfarin is preferred only at a higher CHADS 2 score than currently used. It would seem ethical to perform a large randomized trial of aspirin vs. any of the OAC medications in patients whose recommended OAC strategy would be different using CHA 2 DS 2 -VAS C vs. CHADS 2 scoring systems. In our AF ablation cohort, up to 41.3% of patients would have been candidates for such a study. The outcome of such a study would determine whether the marked increase in the number of patients for whom OAC is recommended by CHA 2 DS 2 -VAS C translates into fewer thrombo-embolic events or instead results in more bleeding complications and/or haemorrhagic strokes.
Limitations
Our study examines the hypothetical effect of the CHA 2 DS 2 -VAS C system on anticoagulation recommendations for a real-world cohort of patients undergoing AF ablation. Although they may not be representative of all AF patients, they may be more representative of ambulatory AF patients than some of the large registry studies of hospitalized AF patients. We examined our patients at only one point in time and patient's risk scores may change over time. We cannot make a determination as to which scoring system is best since all our patients underwent an AF ablation, many had AF eliminated, and those on OAC were not randomized. Current guidelines recommend that post-ablation patients remain on OAC according to their risk scores.
Conclusions
Compared with the CHADS 2 score, the CHA 2 DS 2 -VAS C score markedly increases the number of AF patients for whom DEFINITE-OAC is recommended. In our patient population, this is driven almost exclusively by incorporation of age .65 and female gender into the CHA 2 DS 2 -VAS C score. Vascular disease played only a minor role in changing OAC recommendations, as most vascular disease occurred in patients for whom the CHADS 2 scoring system already recommended DEFINITE-OAC. Even when using the CHA 2 DS 2 -VAS C modifications for anticoagulation recommendations by the 2012 European Guidelines 20 and the recent Canadian Guidelines, 21 our data suggest that CHA 2 DS 2 -VAS C markedly increases the number of patients for whom OAC is recommended. Since the CHA 2 DS 2 -VAS C scoring system results in many more patients recommended for OAC, it will be important to determine by a randomized trial whether the CHA 2 DS 2 -VAS C scoring system's classification scheme results in improved outcomes, without increased morbidity/mortality due to bleeding complications compared with the CHADS 2 score.
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